These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38145455)

  • 1. The efficacy of rituximab plus belimumab or telitacicept in refractory lupus nephritis.
    Chen Y; Shi N; Lei X; Ren P; Lan L; Chen L; Wang Y; Xu Y; Lin Y; Chen J; Han F
    Rheumatology (Oxford); 2023 Dec; ():. PubMed ID: 38145455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of telitacicept in refractory systemic lupus erythematosus patients who failed treatment with belimumab : A case series.
    Fan Q; Yang H; Liu Y
    Z Rheumatol; 2024 Jun; 83(5):387-392. PubMed ID: 38157053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO; Bruce IN; Diamond B; Furie RA; van Vollenhoven RF; Gordon D; Groark J; Henderson RB; Oldham M; Tak PP
    BMJ Open; 2019 Mar; 9(3):e025687. PubMed ID: 30898822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
    van Schaik M; Arends EJ; Soonawala D; van Ommen E; de Leeuw K; Limper M; van Paassen P; Huizinga TWJ; Toes REM; van Kooten C; Rotmans JI; Rabelink TJ; Teng YKO
    Trials; 2022 Nov; 23(1):939. PubMed ID: 36371234
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency and predictors for early-achieved lupus low disease activity state in systemic lupus erythematosus patients treated with telitacicept or belimumab: A real-life, single-center observational study.
    Fan C; Yang T; Zheng S; Liao X; Xie R; Chen S; Li J
    Front Immunol; 2024; 15():1423035. PubMed ID: 38947321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of telitacicept in patients with lupus nephritis.
    Zhu H; Hu HQ; Wei HL; Zhang DX; Yang H; Zhang QK; Jin L
    Exp Ther Med; 2024 Oct; 28(4):371. PubMed ID: 39091632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study.
    Huang X; Lin F; Chen H
    Clin Exp Nephrol; 2024 Sep; 28(9):902-909. PubMed ID: 38613741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis.
    Atisha-Fregoso Y; Malkiel S; Harris KM; Byron M; Ding L; Kanaparthi S; Barry WT; Gao W; Ryker K; Tosta P; Askanase AD; Boackle SA; Chatham WW; Kamen DL; Karp DR; Kirou KA; Sam Lim S; Marder B; McMahon M; Parikh SV; Pendergraft WF; Podoll AS; Saxena A; Wofsy D; Diamond B; Smilek DE; Aranow C; Dall'Era M
    Arthritis Rheumatol; 2021 Jan; 73(1):121-131. PubMed ID: 32755035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to belimumab among patients with refractory lupus nephritis: a real-world observational retrospective multicenter study.
    Zhang S; Qiu Q; Zeng S; Li H; Xu L; Jie L; Hu X; Xiao Y; Chen D; Zhan Z; Liang L; Yu Q; Xu H
    Clin Rheumatol; 2024 Jan; 43(1):199-208. PubMed ID: 37982925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Telitacicept in a systemic lupus erythematosus patient with suboptimal response to Belimumab: A case report.
    Huang L; Qian G; Zhang H; Li Q; Chen L; Tang X; Zhao H
    Lupus; 2024 Feb; 33(2):172-175. PubMed ID: 38081170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cell depletion and inhibition in systemic lupus erythematosus.
    Krustev E; Clarke AE; Barber MRW
    Expert Rev Clin Immunol; 2023 Jan; 19(1):55-70. PubMed ID: 36342225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-cell targeted therapies in systemic lupus erythematosus: successes and challenges.
    Harvey PR; Gordon C
    BioDrugs; 2013 Apr; 27(2):85-95. PubMed ID: 23456653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Refractory lupus hepatitis successfully treated with telitacicept who failed to belimumab: A case report and literature review.
    Fan Q; Ji H; Liu Y; Jia C; Zou L; Yang H
    Lupus; 2024 Apr; 33(4):414-419. PubMed ID: 38320748
    [No Abstract]   [Full Text] [Related]  

  • 14. Efficacy and safety of telitacicept in patients with systemic lupus erythematosus: a multicentre, retrospective, real-world study.
    Jin HZ; Li YJ; Wang X; Li Z; Ma B; Niu L; Wang P; Pan HF; Li SD; Bao W; Wang G; Li XM; Chen Z
    Lupus Sci Med; 2023 Nov; 10(2):. PubMed ID: 38007228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab.
    Hassan SU; Md Yusof MY; Emery P; Dass S; Vital EM
    Front Med (Lausanne); 2020; 7():498. PubMed ID: 32984378
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and Safety of Belimumab in Patients With Lupus Nephritis: Subgroup Analyses of a Phase 3 Randomized Trial in the East Asian Population.
    Yu X; Chen N; Xue J; Mok CC; Bae SC; Peng X; Chen W; Ren H; Li X; Noppakun K; Gilbride JA; Green Y; Ji B; Liu C; Madan A; Okily M; Tang CH; Roth DA
    Am J Kidney Dis; 2023 Mar; 81(3):294-306.e1. PubMed ID: 36058429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus.
    Kraaij T; Kamerling SWA; de Rooij ENM; van Daele PLA; Bredewold OW; Bakker JA; Bajema IM; Scherer HU; Toes REM; Huizinga TJW; Rabelink TJ; van Kooten C; Teng YKO
    J Autoimmun; 2018 Jul; 91():45-54. PubMed ID: 29636274
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report.
    Chen JW; Zhan JY; Liang SP; Wang XD; Lin CS; Xu Q
    Int J Rheum Dis; 2023 Jul; 26(7):1417-1421. PubMed ID: 37218552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab in the treatment of resistant lupus nephritis: therapy failure in rapidly progressive crescentic lupus nephritis.
    Davies RJ; Sangle SR; Jordan NP; Aslam L; Lewis MJ; Wedgwood R; D'Cruz DP
    Lupus; 2013 May; 22(6):574-82. PubMed ID: 23632989
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New onset of lupus nephritis in two patients with SLE shortly after initiation of treatment with belimumab.
    Staveri C; Karokis D; Liossis SC
    Semin Arthritis Rheum; 2017 Jun; 46(6):788-790. PubMed ID: 27793432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.